Why the study?
The study examined native platelet function, its correlation with routine laboratory parameters, and factors linked to poor 90-day outcomes in very elderly patients not on antiplatelet or anticoagulant therapy.
Population
94 very elderly inpatients (≥ 80 years) not on antiplatelet or anticoagulant therapy
Comparison
Patients aged 80–89 years vs ≥ 90 years
Design
Retrospective cohort study
Follow-up
90 days
Key result
In very elderly patients not on antithrombotic therapy, age ≥90 years was not significantly associated with poor 90-day clinical outcomes compared to age 80-89 years (OR 2.86).
Authors
Loading...
Suggests advanced age alone does not alter baseline platelet function; leaves open whether larger cohorts might.
Cohort (n=94)
No
Odds Ratio: 2.86 (95% CI 0.85–9.62)
Absolute Event Rate: 20.5% vs 8%
p-value: p=0.090
In very elderly patients not on antithrombotic therapy, native platelet function does not differ between octogenarians and nonagenarians and does not predict 90-day outcomes, though limited by small sample size.
NanZhu et al. (2026) conducted a cohort in Very elderly patients not on antiplatelet or anticoagulant therapy (n=94). Age ≥90 years vs. Age 80-89 years was evaluated on Poor 90-day clinical outcomes (all-cause mortality, severe disability, or hospital readmission due to MACE) (OR 2.86, 95% CI 0.85-9.62, p=0.090). In very elderly patients not on antithrombotic therapy, age ≥90 years was not significantly associated with poor 90-day clinical outcomes compared to age 80-89 years (OR 2.86).